All Outputs (4)

Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). (2022)
Journal Article
MORROW, G.B. and MUTCH, N.J. 2023. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Seminars in thrombosis and hemostasis [online], 49(3), pages 305-313. Available from: https://doi.org/10.1055/s-0042-1758791

Plasminogen activator inhibitor 1 (PAI-1), a SERPIN inhibitor, is primarily known for its regulation of fibrinolysis. However, it is now known that this inhibitor functions and contributes to many (patho)physiological processes including inflammation... Read More about Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1)..

The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. (2022)
Journal Article
WHYTE, C.S., SIMPSON, M., MORROW, G.B., WALLACE, C.A., MENTZER, A.J., KNIGHT, J.C., SHAPIRO, S., CURRY, N., BAGOT, C.N., WATSON, H., COOPER, J.G. and MUTCH, N.J. 2022. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. Journal of thrombosis and haemostasis [online], 20(10), pages 2394-2406. Available from: https://doi.org/10.1111/jth.15806

Severe COVID-19 disease is associated with thrombotic complications and extensive fibrin deposition. This study investigates whether the hemostatic complications in COVID-19 disease arise due to dysregulation of the fibrinolytic system. This prospect... Read More about The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1..

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial. (2022)
Journal Article
MORROW, G.B., FELLER, T., MCQUILTEN, Z., WAKE, E., ARIËNS, R.A.S., WINEARLS, J., MUTCH, N.J., LAFFAN, M.A. and CURRY, N. 2022. Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial. Critical care [online], 26, article number 290. Available from: https://doi.org/10.1186/s13054-022-04167-x

Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT... Read More about Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial..

Removing plasmin from the equation: something to chew on… (2022)
Journal Article
MORROW, G.B. and MUTCH, N.J. 2022. Removing plasmin from the equation: something to chew on… Journal of thrombosis and haemostasis [online], 20(2), pages 280-284. Available from: https://doi.org/10.1111/jth.15590

Thrombolytics or fibrinolytics are a group of pharmacological agents used to target and dissolve occlusive intravascular thrombi. Thrombi form a haemostatic plug at the site of injury to arrest bleeding and are essential for wound healing. However, i... Read More about Removing plasmin from the equation: something to chew on….